Importantly, FINs like Erastin and RSL3 exhibit selective cytotoxicity toward tumor cells while sparing CD8+ T cells due to intrinsic resistance [607], suggesting novel opportunities for tumor‐specific therapies. The gene discussed is CD8A; the disease is neoplasm.